id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-254580-nhpjvgt4	Ricardo, Jose W.	Considerations for Safety in the Use of Systemic Medications for Psoriasis and Atopic Dermatitis during the COVID‐19 pandemic	2020-05-27		.txt	text/plain	2749	191	43	In this review, we discuss overall infection risks of non‐biologic and biologic systemic medications for psoriasis and atopic dermatitis, and provide therapeutic recommendations. In this review, we summarize the current literature regarding overall infection risks with systemic immunomodulating agents for psoriasis and AD, and provide evidence-based treatment recommendations during the COVID-19 pandemic. 11 While methotrexate and cyclosporine are associated with decreased infection rates and favored over treatment with systemic corticosteroids, 12 their impact on susceptibility to/severity of COVID-19 is unknown and, if essential, precautions should be taken to avoid infection. In a phase III, double-blinded, placebo-controlled study on 837 psoriasis patients randomized to treatment with guselkumab, adalimumab or placebo, overall, candida, and serious infections, occurred at comparable rates across treatment groups. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo-and active comparator-controlled VOYAGE 2 trial	./cache/cord-254580-nhpjvgt4.txt	./txt/cord-254580-nhpjvgt4.txt